Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2509146 | 0.98 | HRH3 (0.46) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL2503262 | 0.92 | CSNK2A2 (0.33) | HRH3SMN1; SMN2 | |
| SCHEMBL2501999 | 0.88 | CARM1 (0.37) | HRH3MAPTCARM1PRMT6PRMT8 | |
| SCHEMBL2501222 | 0.86 | HRH3 (0.39) | HRH3MAPTCARM1PRMT6PRMT8 | |
| SCHEMBL3771444 | 0.85 | KEAP1 (0.47) | HRH3CYP1A2MAPK1SMN1; SMN2KCNH2 | |
| SCHEMBL28789625 | 0.83 | CARM1 (0.32) | HRH3CARM1PRMT6PRMT8 | |
| SCHEMBL2508436 | 0.79 | ALOX15 (0.31) | — | |
| SCHEMBL2503308 | 0.77 | HRH3 (0.45) | HRH3CYP1A2MAPK1SMN1; SMN2KCNH2 | |
| SCHEMBL2503312 | 0.77 | HRH3 (0.45) | HRH3CYP1A2MAPK1SMN1; SMN2KCNH2 | |
| SCHEMBL2500657 | 0.77 | HRH3 (0.45) | HRH3MAPTCARM1PRMT6PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436166-B2 | Amino-containing vinylsilane compounds and making method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-05-07 | — | — | US | disclosed |
| CN-102206304-A | Conjugated diene polymer, conjugated diene polymer composition, and method for producing conjugated diene polymer | SUMITOMO CHEMICAL CO | 2011-10-05 | — | — | CN | disclosed |
| US-20100317852-A1 | AMINO-CONTAINING VINYLSILANE COMPOUNDS AND MAKING METHOD | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317852-A1 | AMINO-CONTAINING VINYLSILANE COMPOUNDS AND MAKING METHOD | BHMT2, GNMT, VASP | HRH3 3252/4885MAPT 2925/4885CARM1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.